A Study of ATG-010 in Combination With ATG-008 in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Yang Yu
Medical Monitor
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Chongqing Cancer Hospital
Chongqing, Chongqing Municipality, China
- Guangzhou First People'S Hospital
Guangzhou, Guangdong, China
- Sun Yat-Sen University Cancer Center
Guangzhou, Guangdong, China
- Hubei Cancer Hospital
Wuhan, Hubei, China
- Hunan Cancer Hospital
Changsha, Hunan, China
- the First Affiliated Hospital of China Medical University
Shenyang, Liaoning, China
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 2 Mar 2022
- Primary completion
- 6 Feb 2023
- Completion
- 8 Feb 2023
- Last update posted
- 17 Mar 2023
- Registered enrollment
- 7
- Registry id
- NCT05354362
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.